Skip to main content
. 2017 Feb 23;15(2):e04694. doi: 10.2903/j.efsa.2017.4694

Table 52.

Prevalence of presumptive ESBL‐ and AmpC‐producing E. coli isolates from meat from bovine animals collected within the specific ESBL‐/AmpC‐/carbapenemase‐producing monitoring and subjected to supplementary testing (Panel 2) in 2015a

Country Total number of samples tested ESBLb ESBL with clavulanic‐SYN only for CTXc ESBL with clavulanic‐SYN only for CAZd AmpCe AmpC + ESBLf
%Prevg %95CI %Prevg %95CI %Prevg %95CI %Prevg %95CI %Prevg %95CI
Austria 234 3 1.2 6.1 0.4 0 2.4 0 0 1.6 0 0 1.6 0 0 1.6
Belgium 91 11.1 3.1 15.2 6.3 1.2 10.9 0 0 4 3.2 0.3 7.7 0 0 4
Bulgaria 461 17.3 0.9 3.7 7.7 0.2 2.2 0 0 0.8 11.5 0.5 2.8 3.8 0.1 1.6
Croatia 150 2.7 0.7 6.7 2 0.4 5.7 0 0 2.4 0 0 2.4 0 0 2.4
Cyprus 122 2.5 0.5 7 0 0 3 0 0 3 6.6 2.9 12.5 0.8 0 4.5
Czech Republic 290 9.3 6.2 13.3 5.2 2.9 8.4 0 0 1.3 4.8 2.7 8 0.3 0 1.9
Denmark 315 2.5 1.1 4.9 1 0.2 2.8 0 0 1.2 0 0 1.2 0 0 1.2
Estonia 150 0.7 0 3.7 0 0 2.4 0 0 2.4 1.3 0.2 4.7 0 0 2.4
Finlandh 300 – 0 1.2 – 0 1.2 – 0 1.2 – 0 1.2 – 0 1.2
France 264 0.4 0 2.1 0.4 0 2.1 0 0 1.4 0 0 1.4 0 0 1.4
Germany 452 3.7 1.7 5.1 1.3 0.4 2.6 0 0 0.8 0.5 0.1 1.6 0.3 0 1.2
Greece 69 1.4 0 7.8 0 0 5.2 0 0 5.2 2.9 0.4 10.1 0 0 5.2
Hungary 268 8.6 5.5 12.6 3.4 1.5 6.3 0 0 1.4 0.7 0.1 2.7 0.4 0 2.1
Latvia 150 6.2 1.9 9.4 2.7 0.4 5.7 0 0 2.4 1.8 0.2 4.7 0 0 2.4
Lithuania 150 7.3 3.2 11.9 4.4 1.5 8.5 0 0 2.4 0.7 0 3.7 0 0 2.4
Netherlands 289 0 0 1.3 0 0 1.3 0 0 1.3 1 0 1.9 0 0 1.3
Portugal 150 7.3 3.7 12.7 4 1.5 8.5 0 0 2.4 0.7 0 3.7 0 0 2.4
Romania 224 12.5 0.5 4.5 6.3 0.1 3.2 0 0 1.6 3.1 0 2.5 3.1 0 2.5
Slovakia 150 0 0 2.4 0 0 2.4 0 0 2.4 2 0.4 5.7 0 0 2.4
Slovenia 150 0.7 0 3.7 0 0 2.4 0 0 2.4 0.7 0 3.7 0 0 2.4
Spain 299 6.9 4.1 10.1 1.7 0.5 3.9 0 0 1.2 2.8 1.2 5.2 0.7 0.1 2.4
Swedenh 289 – 0 1.3 – 0 1.3 – 0 1.3 – 0 1.3 – 0 1.3
United Kingdom 312 1 0 1.8 1 0 1.8 0 0 1.2 1 0 1.8 0 0 1.2
Total (23 MSs) 5,329 5.0 4.4 5.6 2.1 1.7 2.5 0 0 0.1 1.8 1.5 2.2 0.3 0.17 0.49
Norway 244 0.8 0.1 2.9 0.4 0 2.3 0 0 1.5 0.4 0 2.3 0 0 1.5
Switzerland 298 0 0 1.2 0 0 1.2 0 0 1.2 0 0 1.2 0 0 1.2

ESBL: extended‐spectrum beta‐lactamase; SYN: synergy; CTX: cefotaxime; CAZ: ceftazidime; MSs: Member States.

a

According to EUCAST Guidelines (EUCAST, 2013), only isolates showing an MIC > 1 mg/L for cefotaxime and/or ceftazidime (screening breakpoint) were considered (see chapter 1.2.5).

b

All isolates showing clavulanate synergy with cefotaxime, ceftazidime or both compounds, suggesting the presence of an ESBL (independently of the presence of other mechanisms).

c

Isolates showing synergy with cefotaxime only, suggesting the presence of an ESBL with cefotaximase activity.

d

Isolates showing synergy with ceftazidime only, suggesting the presence of an ESBL with ceftazidimase activity.

e

Isolates with microbiological resistance to cefoxitin, suggesting the presence of an AmpC‐enzyme (independently of the presence of other mechanisms).

f

Isolates showing synergy with cefotaxime or ceftazidime and with microbiological resistance to cefoxitin, suggesting the presence of ESBL and AmpC‐enzymes in the same isolate. These isolates are also included in the ESBL and AmpC columns.

g

Percentage of the total number of E. coli isolates tested (with panel 2).

h

Finland and Sweden investigated 300 and 289 samples, respectively. None tested positive.